Search

Syndax Pharmaceuticals Inc

Closed

SectorHealthcare

16.88 -0.47

Overview

Share price change

24h

Current

Min

16.37

Max

17.28

Key metrics

By Trading Economics

Income

-6.7M

-49M

Sales

7.9M

73M

EPS

-0.55

Profit margin

-67.817

Employees

298

EBITDA

-5.9M

-37M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+119.22% upside

Dividends

By Acuity

Next Earnings

2 lis 2026

Market Stats

By TradingEconomics

Market Cap

-125M

1.6B

Previous open

17.35

Previous close

16.88

News Sentiment

By Acuity

77%

23%

302 / 340 Ranking in Healthcare

Syndax Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 paź 2026, 23:20 UTC

Syndax Pharmaceuticals Inc gained modestly in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

6 paź 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, hitting a low of over 5% earlier, and remain below the 20-day moving average.

2 paź 2026, 19:15 UTC

Syndax Pharmaceuticals Inc shares fell sharply, facing significant downward pressure and trading notably below its 20-day moving average amid broader biotechnology sector weakness.

1 paź 2026, 20:07 UTC

Social Media

Shares of Syndax Pharmaceuticals fell despite positive analyst ratings from H.C. Wainwright and Jefferies, remaining below the 20-day moving average.

30 wrz 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is experiencing gains in Wednesday's trading session, rebounding significantly after an early dip and achieving a notable cumulative return since Tuesday.

29 wrz 2026, 23:30 UTC

Syndax Pharmaceuticals Inc is rising in after-market trading, advancing from a low point post-market close and currently near the midpoint of its one-month trading range.

28 wrz 2026, 19:16 UTC

News

Syndax Pharmaceuticals Inc. shares fell, remaining below the 20-day moving average despite being rated a "Strong Buy" following FDA approval for Revuforj.

25 wrz 2026, 19:46 UTC

News
Social Media

Syndax Pharmaceuticals reaffirms over $2 billion in U.S. peak sales for Revuforj after SAVE trial results show an 88% overall response rate, driving shares higher.

24 wrz 2026, 20:12 UTC

Syndax Pharmaceuticals Inc is trading higher in after-market hours, maintaining a steady position since Thursday's close, despite being below its 20-day moving average.

23 wrz 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares fell sharply, reaching their lowest point around midday and remaining below the 20-day moving average after a significant decline from Tuesday's close.

22 wrz 2026, 19:45 UTC

Syndax Pharmaceuticals Inc is trading modestly higher, though the price remains below its 20-day moving average and near the lower end of its one-month range.

21 wrz 2026, 21:11 UTC

Syndax Pharmaceuticals Inc is advancing in after-market trading, reflecting notable upward movement since Monday's close, despite remaining below its 20-day moving average.

17 wrz 2026, 20:07 UTC

Syndax Pharmaceuticals Inc is trading higher, having seen a steady increase, despite being below its 20-day moving average and near the lower end of its one-month range.

16 wrz 2026, 20:06 UTC

Macro Event

Syndax Pharmaceuticals Inc shares fell sharply, driven by heightened volatility in the healthcare sector following the Federal Reserve's recent 25 basis point interest rate hike.

15 wrz 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

11 wrz 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

10 wrz 2026, 20:03 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

8 wrz 2026, 20:07 UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2 wrz 2026, 20:08 UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

1 wrz 2026, 20:09 UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

25 sie 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24 sie 2026, 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21 sie 2026, 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20 sie 2026, 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19 sie 2026, 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18 sie 2026, 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17 sie 2026, 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14 sie 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12 sie 2026, 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11 sie 2026, 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

119.22% upside

12 Months Forecast

Average 37.333 USD  119.22%

High 57 USD

Low 26 USD

Based on 10 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Sentiment

By Acuity

302 / 340 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.